Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): A multicentre phase II trail of the German CLL Study Group (GCLLSG).

被引：6

作者：

Fischer, Kirsien ^{[1
]}

Stilgenbauer, Stephan ^{[2
]}

Schweighofer, Carmen D. ^{[1
]}

Renschler, Jasmin ^{[1
]}

Busch, Raymonde ^{[3
]}

Kiehl, Michael ^{[4
]}

Balleisen, Leopold ^{[5
]}

Eckart, Michael ^{[6
]}

Fink, Anna M. ^{[1
]}

Boettcher, Sebastian ^{[7
]}

Ritgen, Matthias ^{[7
]}

Kneba, Michael ^{[7
]}

Staib, Peter ^{[1
]}

Doehner, Hartmut ^{[2
]}

Eichhorst, Barbara F. ^{[1
]}

Hallek, Michael ^{[1
]}

机构：

[1] Univ Hosp, Dept Internal Med 1, Cologne, Germany

[2] Univ Hosp, Dept Internal Med, Ulm, Germany

[3] Tech Univ, Inst Med Stat & Epidemiol, Munich, Germany

[4] Hospital, Dept Internal Med, Frankfurt, Germany

[5] Hospital, Dept Internal Med, Hamm, Germany

[6] ISP Naegelsbacherstr, Erlangen, Germany

[7] Univ Hosp, Dept Internal Med, Kiel, Germany

来源：

BLOOD | 2007年 / 110卷 / 11期

关键词：

D O I：

10.1182/blood.V110.11.3106.3106

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3106

引用

页码：913A / 914A

页数：2

共 50 条

[41] A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL) [J].

Nabhan, C ;

Patton, D ;

Gordon, LI ;

Riley, MB ;

Kuzel, T ;

Tallman, MS ;

Rosen, ST .

LEUKEMIA & LYMPHOMA, 2004, 45 (11) :2269-2273

[42] Final Analysis of a Phase 2 Study of Lenalidomide and Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) [J].

Badoux, Xavier C. ;

Keating, Michael J. ;

O'Brien, Susan ;

Wierda, William G. ;

Faderl, Stefan ;

Estrov, Zeev ;

Pasia, Manolo ;

Lerner, Susan ;

Sargent, Rachel L. ;

Kantarjian, Hagop M. ;

Ferrajoli, Alessandra .

BLOOD, 2011, 118 (21) :448-448

[43] RITUXIMAB PLUS BENDAMUSTINE IN ELDERLY PATIENTS AFFECTED BY RELAPSED OR REFRACTORY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) [J].

Lucania, A. ;

Villa, M. R. ;

Izzo, G. Nitrato ;

Improta, S. ;

Mastrullo, L. .

HAEMATOLOGICA, 2014, 99 :591-591

[44] Favorable Toxicity Profile and Long Term Outcome of Elderly, but Physically Fit CLL Patients (pts) Receiving First Line Bendamustine and Rituximab (BR) Frontline Chemoimmunotherapy in Comparison to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Advanced Chronic Lymphocytic Leukemia (CLL): Update Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study) [J].

Eichhorst, Barbara F. ;

Bahlo, Jasmin ;

Maurer, Christian ;

Lange, Elisabeth ;

Koppler, Hubert ;

Kiehl, Michael G. ;

Sokler, Martin ;

Schlag, Rudolf ;

Vehling-Kaiser, Ursula ;

Kochling, Georg ;

Ploger, Christoph ;

Gregor, Michael ;

Plesner, Torben ;

Herling, Marco ;

Fischer, Kirsten ;

Dohner, Hartmut ;

Kneba, Michael ;

Wendtner, Clemens ;

Klapper, Wolfram ;

Kreuzer, Karl-Anton ;

Bottcher, Sebastian ;

Stilgenbauer, Stephan ;

Fink, Anna Maria ;

Hallek, Michael .

BLOOD, 2016, 128 (22)

[45] Combination Therapy with Ofatumumab and Lenalidomide in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): Results of a Phase II Trial [J].

Ferrajoli, Alessandra ;

O'Brien, Susan ;

Wierda, William G. ;

Faderl, Stefan ;

Badoux, Xavier ;

Estrov, Zeev ;

Schlette, Ellen ;

Smith, Susan C. ;

Ayala, Ana B. ;

Falchi, Lorenzo ;

Calin, Steliana ;

Kantarjian, Hagop M. ;

Keating, Michael J. .

BLOOD, 2011, 118 (21) :780-780

[46] Final follow-up of a Phase I dose-ranging study of Bendamustine and Rituximab (BR) in patients with chronic lymphocytic leukemia (CLL) with comorbidities [J].

Danilov, Alexey ;

Lewis, Lionel ;

Brown, Jennifer .

LEUKEMIA & LYMPHOMA, 2017, 58 :10-10

[47] Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study [J].

Van Den Neste, Eric ;

Cazin, Bruno ;

Janssens, Ann ;

Gonzalez-Barca, Eva ;

Jose Terol, Maria ;

Levy, Vincent ;

Perez de Oteyza, Jaime ;

Zachee, Pierre ;

Saunders, Andrew ;

de Frias, Merce ;

Campas, Clara .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (03) :581-591

[48] Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study [J].

Eric Van Den Neste ;

Bruno Cazin ;

Ann Janssens ;

Eva González-Barca ;

María José Terol ;

Vincent Levy ;

Jaime Pérez de Oteyza ;

Pierre Zachee ;

Andrew Saunders ;

Mercè de Frias ;

Clara Campàs .

Cancer Chemotherapy and Pharmacology, 2013, 71 :581-591

[49] EFFICACY OF THE COMBINATION OF BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA [J].

Zagoskina, T. ;

Zotina, E. ;

Ovsepyan, V. ;

Shardakov, V. .

HAEMATOLOGICA, 2014, 99 :591-591

[50] A phase I/II study of the SYK inhibitor entospletinib in combination with obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) [J].

Kittai, Adam ;

Hashiguchi, Taylor ;

Thurlow, Bria ;

Gokcora, Basak ;

Stadnik, Andrzej ;

MacKinnon, Renee ;

Stephen, Monette ;

Moore, Lacey ;

Persky, Daniel ;

Park, Byung ;

Spurgeon, Stephen ;

Danilov, Alexey .

LEUKEMIA & LYMPHOMA, 2020, 61 :76-77

← 1 2 3 4 5 →